Tailor-Made cancer therapies tested in unique N-of-1 trial

NCT ID NCT06285500

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers people with advanced or rare cancers a personalized treatment plan based on their tumor's genetic profile. Each participant receives a unique therapy chosen by a team of experts. The goal is to see if these tailored treatments can shrink tumors and help more patients access precision medicine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient-specific treatments based on biomarker test results
What this could lead to: If successful, this could show that personalized, biomarker-driven treatments improve outcomes for people with advanced or rare cancers who have few options.
What could go wrong: This is an early-stage, single-patient design with no control group, so results may not apply broadly. Side effects from experimental treatments are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER RARE DISEASES

Contacts and locations

Locations

University Health Network, Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.